🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "major milestone" in the fight against drug-resistant strains of the bacteria, according to health experts.

A Global Challenge

Gonorrhoea infections are on the rise worldwide, with estimates suggesting in excess of 82 million instances each year. Particularly high rates are reported in the African continent and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary advancement in the reality of rising global incidence, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The World Health Organization has listed it as a "high-priority threat". A tracking program found that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Receive Authorization

One new antibiotic, marketed under the name a brand name, was approved by the US FDA in December for use against gonorrhoea. This disease can lead to significant complications, including infertility. Scientists anticipate that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This treatment, which is also used to treat urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for drug creation. The charitable organization GARDP partnered with the drug firm its industry partner to bring it to fruition.

“This authorization represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Research Study Results and Worldwide Availability

As per findings detailed in a major medical journal, zoliflodacin successfully treated more than 90% of cases of the STI. This establishes an equal footing with the current standard treatment, which uses a dual-drug approach. The study involved hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the rights to register and commercialise the drug in a wide range of developing nations.

Medical professionals directly involved have expressed optimism. Access to a easy-to-administer therapy like this is described as a "game-changer" for managing the epidemic. This is viewed as crucial to reduce the burden of the illness for individuals and to halt the transmission of untreatable gonorrhoea around the world.